Krystal Biotech, Inc. (KRYS) Stock Forecast
KRYS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 12 analysts
- Price target
- $395.44 average of analyst targets
- Upside to target
- +24.9% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $1.88
- 52-week range
- $185.05 – $378.15
KRYS analyst ratings
12 analystsNumber of analysts at each rating.
KRYS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
KRYS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.93 | $1.49 | $3.04 | $2.66 | −27.3% | 10 |
| Current fiscal year (2026) | $7.62 | $6.77 | $10.26 | $6.84 | +11.4% | 11 |
| Next fiscal year (2027) | $9.05 | $6.47 | $12.04 | $7.62 | +18.7% | 11 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
KRYS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $127.2M | $122.8M | $134.4M | +30.0% | 10 |
| Current fiscal year (2026) | $498.2M | $484.2M | $516.4M | +28.0% | 10 |
| Next fiscal year (2027) | $638.3M | $577.3M | $704.8M | +28.1% | 10 |
KRYS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
KRYS revenue: reported and forecast
KRYS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.22 | $2.00 | $2.00 | $1.98 | $1.93 | −13.0% | 0 up · 1 down |
| Current fiscal year (2026) | $8.45 | $7.87 | $7.87 | $7.74 | $7.62 | −9.8% | 0 up · 2 down |
| Next fiscal year (2027) | $10.01 | $9.40 | $9.40 | $9.26 | $9.05 | −9.6% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
KRYS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; KRYS beat in 7 of 12.
What analysts expect from KRYS
12 analysts cover Krystal Biotech; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $395.44, 24.9% above the latest close of $316.58. Analysts expect earnings of $7.62 per share for 2026, +11.4% from a year earlier. For 2027 the average estimate is $9.05 per share on revenue of $638.3 million. Krystal Biotech beat the EPS estimate in 7 of the last 12 quarters.
Related: KRYS income statement, KRYS key metrics, KRYS chart. See the KRYS stock overview for the latest quote and news.
KRYS forecast FAQ
What is Krystal Biotech's price target?
The average analyst price target for Krystal Biotech is $395.44, 24.9% above the latest close of $316.58.
Is Krystal Biotech a buy, hold or sell?
Of 12 analysts covering Krystal Biotech, 10 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Krystal Biotech's EPS forecast?
Analysts forecast $7.62 per share for 2026 (range $6.77 to $10.26); for 2027 the estimate is $9.05.
What is Krystal Biotech's revenue forecast?
The average revenue estimate for 2026 is $498.2 million, growth of 28.0%; for 2027 it is $638.3 million.
When does Krystal Biotech report earnings?
Krystal Biotech is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 before the market opens; the EPS estimate is $1.88.
Does Krystal Biotech usually beat earnings estimates?
Krystal Biotech reported EPS at or above the analyst estimate in 7 of the last 12 quarters.